Matches in SemOpenAlex for { <https://semopenalex.org/work/W2767492717> ?p ?o ?g. }
Showing items 1 to 83 of
83
with 100 items per page.
- W2767492717 endingPage "e21" @default.
- W2767492717 startingPage "e16" @default.
- W2767492717 abstract "Although FOLFIRINOX is a standard treatment option for advanced pancreas cancer, there are few data describing utilisation and effectiveness in routine clinical practice. Here we report practice patterns and outcomes in the general population of Ontario, Canada.Using the Ontario Cancer Registry and New Drug Funding Program, we identified all patients with pancreas cancer treated with palliative intent gemcitabine or FOLFIRINOX in Ontario during 2006-2014. FOLFIRINOX became available in Ontario's single-payer health system in November 2011. Gemcitabine cases were classified as pre-FOLFIRINOX era (2006-2010) or post-FOLFIRINOX era (2011-2014). Cases treated with perioperative chemotherapy were excluded. Comparisons of proportions between study groups were made using the chi-square test. Overall survival was measured from the date of chemotherapy initiation.During 2006-2014, 3826 patients in Ontario were treated with gemcitabine (n = 3042) or FOLFIRINOX (n = 784) chemotherapy for advanced pancreas cancer. Uptake of FOLFIRINOX increased from 41% (206/505) of treated cases in 2012 to 56% (274/486) of treated cases in 2014. The median overall survival of patients treated with gemcitabine was 5.0 months in 2006-2010 and 4.8 months in 2011-2014. The median overall survival of FOLFIRINOX patients treated in 2011-2014 was 8.2 months.The use of FOLFIRINOX in the general population has increased since 2011. Survival outcomes show a substantial efficacy-effectiveness gap between the pivotal Prodige 4/ACCORD 11 clinical trial and routine practice." @default.
- W2767492717 created "2017-11-17" @default.
- W2767492717 creator A5022724853 @default.
- W2767492717 creator A5025627496 @default.
- W2767492717 creator A5043396408 @default.
- W2767492717 creator A5061933475 @default.
- W2767492717 creator A5089899558 @default.
- W2767492717 date "2018-01-01" @default.
- W2767492717 modified "2023-09-26" @default.
- W2767492717 title "Uptake and Effectiveness of FOLFIRINOX for Advanced Pancreatic Cancer: a Population-based Study" @default.
- W2767492717 cites W1931508686 @default.
- W2767492717 cites W1967411786 @default.
- W2767492717 cites W2027389238 @default.
- W2767492717 cites W2037489171 @default.
- W2767492717 cites W2049756688 @default.
- W2767492717 cites W2151253787 @default.
- W2767492717 cites W2165480504 @default.
- W2767492717 cites W2165948908 @default.
- W2767492717 cites W2317504614 @default.
- W2767492717 cites W2333616930 @default.
- W2767492717 cites W2415398754 @default.
- W2767492717 cites W2480793872 @default.
- W2767492717 cites W4210976084 @default.
- W2767492717 doi "https://doi.org/10.1016/j.clon.2017.10.017" @default.
- W2767492717 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29137884" @default.
- W2767492717 hasPublicationYear "2018" @default.
- W2767492717 type Work @default.
- W2767492717 sameAs 2767492717 @default.
- W2767492717 citedByCount "14" @default.
- W2767492717 countsByYear W27674927172019 @default.
- W2767492717 countsByYear W27674927172020 @default.
- W2767492717 countsByYear W27674927172021 @default.
- W2767492717 countsByYear W27674927172023 @default.
- W2767492717 crossrefType "journal-article" @default.
- W2767492717 hasAuthorship W2767492717A5022724853 @default.
- W2767492717 hasAuthorship W2767492717A5025627496 @default.
- W2767492717 hasAuthorship W2767492717A5043396408 @default.
- W2767492717 hasAuthorship W2767492717A5061933475 @default.
- W2767492717 hasAuthorship W2767492717A5089899558 @default.
- W2767492717 hasConcept C121608353 @default.
- W2767492717 hasConcept C126322002 @default.
- W2767492717 hasConcept C143998085 @default.
- W2767492717 hasConcept C2777148230 @default.
- W2767492717 hasConcept C2780210213 @default.
- W2767492717 hasConcept C2780258809 @default.
- W2767492717 hasConcept C2780259306 @default.
- W2767492717 hasConcept C2908647359 @default.
- W2767492717 hasConcept C526805850 @default.
- W2767492717 hasConcept C71924100 @default.
- W2767492717 hasConcept C99454951 @default.
- W2767492717 hasConceptScore W2767492717C121608353 @default.
- W2767492717 hasConceptScore W2767492717C126322002 @default.
- W2767492717 hasConceptScore W2767492717C143998085 @default.
- W2767492717 hasConceptScore W2767492717C2777148230 @default.
- W2767492717 hasConceptScore W2767492717C2780210213 @default.
- W2767492717 hasConceptScore W2767492717C2780258809 @default.
- W2767492717 hasConceptScore W2767492717C2780259306 @default.
- W2767492717 hasConceptScore W2767492717C2908647359 @default.
- W2767492717 hasConceptScore W2767492717C526805850 @default.
- W2767492717 hasConceptScore W2767492717C71924100 @default.
- W2767492717 hasConceptScore W2767492717C99454951 @default.
- W2767492717 hasIssue "1" @default.
- W2767492717 hasLocation W27674927171 @default.
- W2767492717 hasLocation W27674927172 @default.
- W2767492717 hasOpenAccess W2767492717 @default.
- W2767492717 hasPrimaryLocation W27674927171 @default.
- W2767492717 hasRelatedWork W1883975635 @default.
- W2767492717 hasRelatedWork W2012954058 @default.
- W2767492717 hasRelatedWork W2476389627 @default.
- W2767492717 hasRelatedWork W2599910524 @default.
- W2767492717 hasRelatedWork W2908011862 @default.
- W2767492717 hasRelatedWork W2910998150 @default.
- W2767492717 hasRelatedWork W3045328550 @default.
- W2767492717 hasRelatedWork W3092133951 @default.
- W2767492717 hasRelatedWork W3184807956 @default.
- W2767492717 hasRelatedWork W4380150473 @default.
- W2767492717 hasVolume "30" @default.
- W2767492717 isParatext "false" @default.
- W2767492717 isRetracted "false" @default.
- W2767492717 magId "2767492717" @default.
- W2767492717 workType "article" @default.